Walter J. Rushlow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Walter J. Rushlow has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Laurie P. Sutton
Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD 21250, USA
5 shared publications N. Rajakumar
Department of Anatomy & Cell Biology, The University of Western Ontario, 1151 Richmond Street, London, Ontario, Canada, N6A 5C1
3 shared publicationsA. Bjelica
Department of Anatomy & Cell Biology, The University of Western Ontario, 1151 Richmond Street, London, Ontario, Canada, N6A 5C1
1 shared publicationC. Seah
Department of Psychiatry, London Health Sciences Centre-University Campus, 339 Windermere Road, London, Ontario, Canada, N6A 5A5
1 shared publicationD. J. Belliveau
Anatomy and Cell Biology, The University of Western Ontario and the London Health Sciences Centres, London, Ontario, Canada
1 shared publicationDariush Honardoust
Psychiatry, The University of Western Ontario, London, Ontario, Canada
1 shared publication
Latest Publications
- 1 June 2022
- Published by Oxford University Press (OUP) in Cerebral Cortex
- Vol. 33 (6) , 2470-2484
Identification of a novel fatty acid binding protein-5-CB2 receptor-dependent mechanism regulating anxiety behaviors in the prefrontal cortex
The endocannabinoid (eCB) system represents a promising neurobiological target for novel anxiolytic pharmacotherapies. Previous clinical and preclinical evidence has revealed that genetic and/or pharmacological manipulations altering eCB signaling modulate fear and anxiety behaviors. Water-insoluble eCB lipid anandamide requires chaperone proteins for its intracellular transport to degradation, a process that requires fatty acid-binding proteins (FABPs). Here, we investigated the effects of a novel FABP-5 inhibitor, SBFI-103, on fear and anxiety-related behaviors using rats. Acute intra-prelimbic cortex administration of SBFI-103 induced a dose-dependent anxiolytic response and reduced contextual fear expression. Surprisingly, both effects were reversed when a cannabinoid-2 receptor (CB2R) antagonist, AM630, was co-infused with SBFI-103. Co-infusion of the cannabinoid-1 receptor antagonist Rimonabant with SBFI-103 reversed the contextual fear response yet showed no reversal effect on anxiety. Furthermore, in vivo neuronal recordings revealed that intra-prelimbic region SBFI-103 infusion altered the activity of putative pyramidal neurons in the basolateral amygdala and ventral hippocampus, as well as oscillatory patterns within these regions in a CB2R-dependent fashion. Our findings identify a promising role for FABP5 inhibition as a potential target for anxiolytic pharmacotherapy. Furthermore, we identify a novel, CB2R-dependent FABP-5 signaling pathway in the PFC capable of strongly modulating anxiety-related behaviors and anxiety-related neuronal transmission patterns.
- 1 June 2022
- Published by Oxford University Press (OUP) in Cerebral Cortex
- Vol. 33 (6) , 2470-2484
Identification of a novel fatty acid binding protein-5-CB2 receptor-dependent mechanism regulating anxiety behaviors in the prefrontal cortex
The endocannabinoid (eCB) system represents a promising neurobiological target for novel anxiolytic pharmacotherapies. Previous clinical and preclinical evidence has revealed that genetic and/or pharmacological manipulations altering eCB signaling modulate fear and anxiety behaviors. Water-insoluble eCB lipid anandamide requires chaperone proteins for its intracellular transport to degradation, a process that requires fatty acid-binding proteins (FABPs). Here, we investigated the effects of a novel FABP-5 inhibitor, SBFI-103, on fear and anxiety-related behaviors using rats. Acute intra-prelimbic cortex administration of SBFI-103 induced a dose-dependent anxiolytic response and reduced contextual fear expression. Surprisingly, both effects were reversed when a cannabinoid-2 receptor (CB2R) antagonist, AM630, was co-infused with SBFI-103. Co-infusion of the cannabinoid-1 receptor antagonist Rimonabant with SBFI-103 reversed the contextual fear response yet showed no reversal effect on anxiety. Furthermore, in vivo neuronal recordings revealed that intra-prelimbic region SBFI-103 infusion altered the activity of putative pyramidal neurons in the basolateral amygdala and ventral hippocampus, as well as oscillatory patterns within these regions in a CB2R-dependent fashion. Our findings identify a promising role for FABP5 inhibition as a potential target for anxiolytic pharmacotherapy. Furthermore, we identify a novel, CB2R-dependent FABP-5 signaling pathway in the PFC capable of strongly modulating anxiety-related behaviors and anxiety-related neuronal transmission patterns.
- Open Access
- 22 July 2011
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 15 (07) , 965-979
The dopamine D2 receptor regulates Akt and GSK-3 via Dvl-3
The dopamine D2 receptor (D2DR) regulates Akt and may also target the Wnt pathway, two signalling cascades that inhibit glycogen synthase kinase-3 (GS
- 22 July 2011
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 15 (07) , 965-979
Open AccessThe dopamine D2 receptor regulates Akt and GSK-3 via Dvl-3
The dopamine D2 receptor (D2DR) regulates Akt and may also target the Wnt pathway, two signalling cascades that inhibit glycogen synthase kinase-3 (GS
- 13 May 2011
- Published by Wiley in Journal of Neurochemistry
- Vol. 117 (6) , 973-983
Regulation of Akt and Wnt signaling by the group II metabotropic glutamate receptor antagonist LY341495 and agonist LY379268
J. Neurochem.(2011)117, 973–983. Metabotropic glutamate receptors 2/3 (mGlu2/3) have been implicated in schizophrenia and as a novel treatment target for schizophrenia. The current study examined whether mGlu2/3regulates Akt (protein kinase B) and Wnt (Wingless/Int‐1) signaling, two cascades associated with schizophrenia and modified by antipsychotics. Western blotting revealed increases in phosphorylated Akt (pAkt) and phosphorylated glycogen synthase kinase‐3 (pGSK‐3) following acute and repeated treatment of LY379268 (mGlu2/3agonist), whereas increases in dishevelled‐2 (Dvl‐2), dishevelled‐3 (Dvl‐3), GSK‐3 and β‐catenin were only observed following repeated treatment. LY341495 (mGlu2/3antagonist) induced the opposite response compared with LY379268. Co‐immunoprecipitation experiments showed an association between the mGlu2/3complex and Dvl‐2 providing a possible mechanism to explain how the mGlu2/3can mediate changes in Wnt signaling. However, there was no association between the mGlu2/3complex and Akt suggesting that changes in Akt signaling following LY341495 and LY379268 treatments may not be directly mediated by the mGlu2/3. Finally, an increase in locomotor activity induced by LY341495 treatment correlated with increased pAkt and pGSK‐3 levels and was attenuated by the administration of the GSK‐3 inhibitor, SB216763. Overall, the results suggest that mGlu2/3regulates Akt and Wnt signaling and LY379268 treatment has overlapping effects with D2dopamine receptor antagonists (antipsychotic drugs).
- 13 May 2011
- Published by Wiley in Journal of Neurochemistry
- Vol. 117 (6) , 973-983
Regulation of Akt and Wnt signaling by the group II metabotropic glutamate receptor antagonist LY341495 and agonist LY379268
J. Neurochem.(2011)117, 973–983. Metabotropic glutamate receptors 2/3 (mGlu2/3) have been implicated in schizophrenia and as a novel treatment target for schizophrenia. The current study examined whether mGlu2/3regulates Akt (protein kinase B) and Wnt (Wingless/Int‐1) signaling, two cascades associated with schizophrenia and modified by antipsychotics. Western blotting revealed increases in phosphorylated Akt (pAkt) and phosphorylated glycogen synthase kinase‐3 (pGSK‐3) following acute and repeated treatment of LY379268 (mGlu2/3agonist), whereas increases in dishevelled‐2 (Dvl‐2), dishevelled‐3 (Dvl‐3), GSK‐3 and β‐catenin were only observed following repeated treatment. LY341495 (mGlu2/3antagonist) induced the opposite response compared with LY379268. Co‐immunoprecipitation experiments showed an association between the mGlu2/3complex and Dvl‐2 providing a possible mechanism to explain how the mGlu2/3can mediate changes in Wnt signaling. However, there was no association between the mGlu2/3complex and Akt suggesting that changes in Akt signaling following LY341495 and LY379268 treatments may not be directly mediated by the mGlu2/3. Finally, an increase in locomotor activity induced by LY341495 treatment correlated with increased pAkt and pGSK‐3 levels and was attenuated by the administration of the GSK‐3 inhibitor, SB216763. Overall, the results suggest that mGlu2/3regulates Akt and Wnt signaling and LY379268 treatment has overlapping effects with D2dopamine receptor antagonists (antipsychotic drugs).
- 1 July 2009
- Published by Elsevier in Neuroscience
- Vol. 161 (3) , 877-886
Antipsychotics affect multiple calcium calmodulin dependent proteins
- 1 July 2009
- Published by Elsevier in Neuroscience
- Vol. 161 (3) , 877-886
Antipsychotics affect multiple calcium calmodulin dependent proteins
- 26 February 2007
- Published by Wiley in Journal of Neurochemistry
- Vol. 102 (1) , 153-169
Activation of the canonical Wnt pathway by the antipsychotics haloperidol and clozapine involves dishevelled‐3
Protein kinase B (Akt), glycogen synthase kinase‐3 (GSK‐3) and members of the Wnt signal transduction pathway were recently found to be altered in schizophrenia and targeted by antipsychotic drugs. In the current study, selected Wnt signalling proteins were investigated to determine if they are altered by the antipsychotics clozapine or haloperidol in the rat prefrontal cortex. Pheochromocytoma (PC12) and neuroblastoma (SH‐SY5Y) cells were also used to elucidate how antipsychotics generated the pattern of changes observedin vivo. Western blotting (WB) revealed that treatment with haloperidol or clozapine caused an up‐regulation of Wnt‐5a, dishevelled‐3, Axin, total and phosphorylated GSK‐3 and β‐catenin protein levels. Treatment of PC12 and SH‐SY5Y cells with a variety of pharmacological agents as well as the over‐expression of several Wnt related proteins failed to mimic the pattern observedin vivofollowing antipsychotic treatment. However, the over‐expression of dishevelled‐3 nearly perfectly duplicated the changes observedin vivo. Immunoprecipitations (IP) conducted using protein isolated from the rat prefrontal cortex indicated that dishevelled‐3 is associated with the D2dopamine receptor thereby suggesting that antipsychotics may act on dishevelled‐3 via D2dopamine receptors to initiate a cascade of downstream changes involving Axin, GSK‐3 and β‐catenin that may help to alleviate psychosis in schizophrenic patients.
- 26 February 2007
- Published by Wiley in Journal of Neurochemistry
- Vol. 102 (1) , 153-169
Activation of the canonical Wnt pathway by the antipsychotics haloperidol and clozapine involves dishevelled‐3
Protein kinase B (Akt), glycogen synthase kinase‐3 (GSK‐3) and members of the Wnt signal transduction pathway were recently found to be altered in schizophrenia and targeted by antipsychotic drugs. In the current study, selected Wnt signalling proteins were investigated to determine if they are altered by the antipsychotics clozapine or haloperidol in the rat prefrontal cortex. Pheochromocytoma (PC12) and neuroblastoma (SH‐SY5Y) cells were also used to elucidate how antipsychotics generated the pattern of changes observedin vivo. Western blotting (WB) revealed that treatment with haloperidol or clozapine caused an up‐regulation of Wnt‐5a, dishevelled‐3, Axin, total and phosphorylated GSK‐3 and β‐catenin protein levels. Treatment of PC12 and SH‐SY5Y cells with a variety of pharmacological agents as well as the over‐expression of several Wnt related proteins failed to mimic the pattern observedin vivofollowing antipsychotic treatment. However, the over‐expression of dishevelled‐3 nearly perfectly duplicated the changes observedin vivo. Immunoprecipitations (IP) conducted using protein isolated from the rat prefrontal cortex indicated that dishevelled‐3 is associated with the D2dopamine receptor thereby suggesting that antipsychotics may act on dishevelled‐3 via D2dopamine receptors to initiate a cascade of downstream changes involving Axin, GSK‐3 and β‐catenin that may help to alleviate psychosis in schizophrenic patients.
- 12 September 2005
- Published by Wiley in Journal of Neurochemistry
- Vol. 95 (2) , 513-525
The effects of antipsychotics on β‐catenin, glycogen synthase kinase‐3 and dishevelled in the ventral midbrain of rats
Protein kinase B and glycogen synthase kinase‐3 have been identified as susceptibility genes for schizophrenia and altered protein and mRNA levels have been detected in the brains of schizophrenics post‐mortem. Recently, we reported that haloperidol, clozapine and risperidone alter glycogen synthase kinase‐3 and β‐catenin protein expression and glycogen synthase kinase‐3 phosphorylation levels in the rat prefrontal cortex and striatum. In the current study, β‐catenin, adenomatous polyposis coli, Wnt1, dishevelled and glycogen synthase kinase‐3 were examined in the ventral midbrain and hippocampus using western blotting. In addition, β‐catenin and GSK‐3 were examined in the substantia nigra and ventral tegmental area using confocal and fluorescence microscopy. The results indicate that repeated antipsychotic administration results in significant elevations in glycogen synthase kinase‐3, β‐catenin and dishevelled‐3 protein levels in the ventral midbrain and hippocampus. Raclopride causes similar changes in β‐catenin and GSK‐3 in the ventral midbrain, suggesting that D2 dopamine receptor antagonism mediated the changes observed following antipsychotic administration. In contrast, amphetamine, a drug capable of inducing psychotic episodes, had the opposite effect on β‐catenin and GSK‐3 in the ventral midbrain. Collectively, the results suggest that antipsychotics may exert their beneficial effects through modifications to proteins that are associated with the canonical Wnt pathway.
- 12 September 2005
- Published by Wiley in Journal of Neurochemistry
- Vol. 95 (2) , 513-525
The effects of antipsychotics on β‐catenin, glycogen synthase kinase‐3 and dishevelled in the ventral midbrain of rats
Protein kinase B and glycogen synthase kinase‐3 have been identified as susceptibility genes for schizophrenia and altered protein and mRNA levels have been detected in the brains of schizophrenics post‐mortem. Recently, we reported that haloperidol, clozapine and risperidone alter glycogen synthase kinase‐3 and β‐catenin protein expression and glycogen synthase kinase‐3 phosphorylation levels in the rat prefrontal cortex and striatum. In the current study, β‐catenin, adenomatous polyposis coli, Wnt1, dishevelled and glycogen synthase kinase‐3 were examined in the ventral midbrain and hippocampus using western blotting. In addition, β‐catenin and GSK‐3 were examined in the substantia nigra and ventral tegmental area using confocal and fluorescence microscopy. The results indicate that repeated antipsychotic administration results in significant elevations in glycogen synthase kinase‐3, β‐catenin and dishevelled‐3 protein levels in the ventral midbrain and hippocampus. Raclopride causes similar changes in β‐catenin and GSK‐3 in the ventral midbrain, suggesting that D2 dopamine receptor antagonism mediated the changes observed following antipsychotic administration. In contrast, amphetamine, a drug capable of inducing psychotic episodes, had the opposite effect on β‐catenin and GSK‐3 in the ventral midbrain. Collectively, the results suggest that antipsychotics may exert their beneficial effects through modifications to proteins that are associated with the canonical Wnt pathway.
- 22 June 2005
- Published by Wiley in Journal of Neurochemistry
- Vol. 94 (3) , 587-596
Changes in calcineurin expression induced in the rat brain by the administration of antipsychotics
Calcineurin (CN) was recently identified as a susceptibility gene for schizophrenia as well as showing altered RNA expression levels in the post-mortem brains of individuals with schizophrenia. CN knockout mice show a number of behaviours associated with schizophrenia, including deficits in sensorimotor gating, suggesting a link between CN and psychosis. Concurrently, we found, using genome screening techniques, that antipsychotics alter CN expression levels. Therefore, western blotting, in situ hybridization, immunocytochemistry and phosphatase assays were employed to determine what effect antipsychotics have on CN. The results indicate that clozapine, risperidone and haloperidol cause substantial reductions in the A subunit of CN but not CN B at both the RNA and protein levels in the striatum and prefrontal cortex. The changes could only be observed after repeated treatment with antipsychotics but not after acute administration. The alterations in CN protein levels were specific to antipsychotics and mediated by D2 dopamine receptor antagonism. However, despite reductions in CN protein levels, the phosphatase activity of CN was significantly elevated after treatment with antipsychotics. Collectively the results suggest that CN may be a common target for antipsychotics and that antipsychotic-induced alterations in CN may represent one of the mechanisms by which antipsychotics alleviate psychosi
- 22 June 2005
- Published by Wiley in Journal of Neurochemistry
- Vol. 94 (3) , 587-596
Changes in calcineurin expression induced in the rat brain by the administration of antipsychotics
Calcineurin (CN) was recently identified as a susceptibility gene for schizophrenia as well as showing altered RNA expression levels in the post-mortem brains of individuals with schizophrenia. CN knockout mice show a number of behaviours associated with schizophrenia, including deficits in sensorimotor gating, suggesting a link between CN and psychosis. Concurrently, we found, using genome screening techniques, that antipsychotics alter CN expression levels. Therefore, western blotting, in situ hybridization, immunocytochemistry and phosphatase assays were employed to determine what effect antipsychotics have on CN. The results indicate that clozapine, risperidone and haloperidol cause substantial reductions in the A subunit of CN but not CN B at both the RNA and protein levels in the striatum and prefrontal cortex. The changes could only be observed after repeated treatment with antipsychotics but not after acute administration. The alterations in CN protein levels were specific to antipsychotics and mediated by D2 dopamine receptor antagonism. However, despite reductions in CN protein levels, the phosphatase activity of CN was significantly elevated after treatment with antipsychotics. Collectively the results suggest that CN may be a common target for antipsychotics and that antipsychotic-induced alterations in CN may represent one of the mechanisms by which antipsychotics alleviate psychosi